Three-dimensional quantification of intratumoral T cells by use of two-photon laser scanning microscopy (TPLSM) demonstrated that intravenously administered anti-CD19 CAR T cells accumulated in limited numbers at a late time point, at levels equal to mock CAR T cells, resulting in tumor regression in a fraction of treated mice. The gene discussed is CD19; the disease is neoplasm.